Loading
Korean lung cancer specialist who led CHRYSALIS, the first human study of amivantamab, whose exon 20 insertion cohort earned the drug its first approval.
Keunchil Park is a thoracic medical oncologist at Samsung Medical Center in Seoul. He was first author of the 2021 Journal of Clinical Oncology report of the CHRYSALIS study, which showed that the EGFR-MET bispecific antibody amivantamab produced durable responses in EGFR exon 20 insertion non-small-cell lung cancer after platinum chemotherapy, the basis of the drug's first approval. He has led many EGFR-directed lung cancer trials in Asia.
| Title | Journal | Year |
|---|---|---|
| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Europe PMC author record matched by affiliation (Samsung Medical Center); 3857 citations on Europe PMC. | The Lancet | 2017 |
| Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial Europe PMC author record matched by affiliation (Samsung Medical Center); 2326 citations on Europe PMC. | The Lancet | 2016 |
| Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer Europe PMC author record matched by affiliation (Samsung Medical Center); 2265 citations on Europe PMC. | New England Journal of Medicine | 2019 |
One of the most cited papers Europe PMC returns for Keunchil Park at Samsung Medical Center, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
One of the most cited papers Europe PMC returns for Keunchil Park at Samsung Medical Center, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
One of the most cited papers Europe PMC returns for Keunchil Park at Samsung Medical Center, so it is a natural starting point for reading their work. The record was linked automatically from the author list and affiliation; read the abstract above and the paper itself before relying on any figure.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, targeted-therapy, trialist.
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tags lung, trialist.
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.